SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a mix of factors, including a reported record demand for its $25B bond sale aimed at funding AI expansion, and discussions around Zuckerberg's hints at selling compute power. Community chatter revolves around whether the AI spending is justified and if the stock's dip presents a buying opportunity, with some citing the company's cheap valuation compared to its peers. Despite positive revenue, a one-time tax bill seems to be weighing on sentiment.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors anticipate the company's earnings report, with debates swirling around potential IV crush and the impact of ad revenue performance. Community members are weighing bullish predictions against concerns of a possible pullback, influenced by Meta's recent performance. Discussions also include the potential for a Google AI deal to boost the stock.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty ($QKITTY) is trending amid discussions about its upcoming DEX and SWAP features, with the community expressing excitement for potential updates and passively earning interest via its trading bot. Despite some users reporting losses, the overall sentiment is optimistic, particularly within the Solana ecosystem.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards after earnings revealed soft traffic trends and a cautious outlook, sparking concerns about revenue and margins. The community is discussing whether this drop is an overreaction or a reflection of deeper issues with the company's value proposition amid rising costs and competition. Some believe the stock is now a buying opportunity while others worry about long-term growth.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed buyout rumors, with some traders citing a STAT News report about the company being in talks for a deal. The community is actively debating the validity of these rumors and potential acquisition prices. Some investors also point to the company's pipeline beyond COVID-19 vaccines and short squeeze potential as reasons for optimism.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates the impact of recent market movements and potential catalysts. Discussions revolve around whether the current dip is a temporary setback or signals a larger shift, with some traders pointing to technical indicators and potential manipulation, while others remain optimistic about long-term fundamentals and broader institutional adoption. Traders are also monitoring macro factors like interest rate decisions and geopolitical events for their potential impact.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending amid discussions of a potential short squeeze and positive financial outlook, including raised EBITDA guidance for 2025. Community members are actively debating price targets and the possibility of a significant rally, citing the company's low PE ratio and potential for multiple expansion. Some are attributing the stock's movement to broader trends in the bio sector and optimism surrounding future earnings reports.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending downwards as investors express concerns about its high short interest, potential impact from interest rate cuts, and broader issues within the fintech sector; despite positive earnings, the stock faces headwinds. Community members are actively debating whether the dip represents a buying opportunity ahead of upcoming earnings or a sign of further decline, with some predicting a short squeeze and others anticipating new lows. Discussions also involve the company's partnerships with credit unions and its AI-driven underwriting model amid softer credit conditions.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal ($PYPL) is trending amid mixed reactions to recent earnings, a new dividend announcement, and partnerships with OpenAI and Google. While some investors see the partnerships and buybacks as bullish signals and potential for long-term growth, others express frustration with the stock's historical performance and question its ability to sustain gains, pointing to broader market sentiment and sector concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

Equity

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of advanced-stage cervical cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">Merck</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1366/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_21_at_11_37_27_AM_png_3a0152bdf1.webp" alt="MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits" width="1366" height="128"><figcaption>MRK's Sentiment Meter and Message Volume as of 11:37 a.m. ET on July 21, 2025 | Source: Stocktwits</figcaption></figure>The approval is <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newswire.ca/news-releases/health-canada-approves-keytruda-r-for-the-treatment-of-adult-patients-with-figo-2014-stage-iii-iva-cervical-cancer-in-combination-with-chemoradiotherapy-crt-1-810218043.html">based</a> on data from the late-stage trial. The data demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to Keytruda in combination with CRT compared with patients randomized to placebo plus CRT. The trial enrolled 1,060 newly diagnosed patients.Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus. In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease, as per data from the Canadian Cancer Society.Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas.Meanwhile, Merck will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. Analysts on average expect the company to report earnings per share of $2.02, down from $2.28 per share in the corresponding quarter of 2024.Quarterly revenue is expected to be $15.86 billion, down from the $16.11 billion reported in the corresponding period of 2024.On Stocktwits, a user expressed optimism about the stock in light of the company’s restructuring plan, upcoming trial results, and solid financial position.<stembedurl>https://stocktwits.com/jjokerst/message/621710390</stembedurl>Another, however, sounded skeptical about the overall pharmaceutical and medical technology industry.<a href="https://stocktwits.com/YouOnlyLiveTwice/message/621754509">https://stocktwits.com/YouOnlyLiveTwice/message/621754509</a>Keytruda is Merck’s blockbuster cancer drug. In the three months through the end of March, Keytruda sales increased 4% to $7.2 billion, driven by a rise in global uptake in earlier-stage indications and continued strong demand worldwide.Through full year 2024, Keytruda total sales were $29.48 billion, accounting for about 46% of the company’s total sales.MRK stock is down 20% this year and approximately 37% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-sees-28-percent-slide-in-chatter-over-past-week/ch8kz4ZR5qy">Tesla Stock Sees 28% Slide In Retail Chatter Over Past Week Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided

Keytruda was first approved in Canada in 2015 and is approved for the treatment of several cancers affecting the bladder, lung, breast, head and neck, and other areas. 

The U.S. Food and Drug Administration may reportedly fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other countries.FDA Commissioner Marty Makary floated the idea in an <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-11/fda-offers-to-trade-faster-drug-reviews-for-lower-us-prices">interview</a> on Bloomberg Television. Makary said that price adjustments may give companies another way to obtain “national priority vouchers” under the program announced last month.As part of the <a href="https://stocktwits.com/news-articles/markets/equity/fda-aims-to-reduce-drug-application-review-time-with-new-voucher-program/chlp5PzRRce">program</a>, the FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten the review time from approximately 10-12 months to one or two months after the company submits its final drug application.According to the initial plan, the agency will distribute a limited number of vouchers to companies aligned with the U.S.’ national priorities in the first year, the FDA stated, without naming any specific companies.“We can issue a national priority review voucher for companies that are promising to equalize the price” between the US and what other foreign countries pay, Makary said.“We want to incentivize good behavior in the marketplace, and these priority vouchers are worth a lot of money,” he added while noting that the program could be used as a means to even out drug prices with those currently charged in places like Europe.Trump <a href="https://stocktwits.com/news-articles/markets/equity/merck-pfizer-eli-lilly-stocks-rebound-as-trump-targets-drug-costs-with-new-executive-order/chiN18ERbmL">signed</a> an executive order in May intended to match U.S. drug prices with those of other developed countries in order to lower domestic healthcare costs.“The United States has less than five percent of the world’s population and yet funds around three-quarters of global pharmaceutical profits,” Trump said.“Americans will no longer be forced to pay almost three times more for the exact same medicines, often made in the exact same factories. As the largest purchaser of pharmaceuticals, Americans should get the best deal.”Makary, on Friday, did not detail how drugmakers have to adjust prices to qualify for a voucher, Bloomberg said. The report added that it is also unclear how much of an impact the vouchers would have and that the FDA has typically avoided entering drug pricing in the U.S.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/mink-therapeutics-patient-received-full-remission-in-testicular-cancer-with-investigational-cell-therapy/ch8cWyDR5Zt">MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report

FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Invesco Capital Management LLC - Invesco Pharmaceuticals ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

PJP
Invesco Dynamic Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PJP News

PJPInvesco Dynamic Pharmaceuticals ETF